Immune response after SARS-CoV-2 infection in users from the ecuadorian coast

Authors

Juan Carlos Mero Velásquez Hospital Básico Chone, Laboratorio Clínico, Chone, Manabí, Ecuador. https://orcid.org/0000-0002-8478-7546
Miguel Àngel Arteaga Quiroz Departamento de Ciencias Biológicas. Facultad de Ciencias de la Salud. Universidad Técnica de Manabí, Portoviejo, Manabí, Ecuador. https://orcid.org/0000-0001-9129-8321

DOI:

https://doi.org/10.33936/qkrcs.v7i2.5804

Keywords:

COVID-19, Ecuador, adaptive immunity, SARS-CoV-2.

Abstract

Coronavirus disease 2019 is a cause of severe acute respiratory syndrome infection. More than 90% of infected people develop antibodies one week after the onset of symptoms, which persist for at least 3 months. However, the persistence of this immune response is limited or questioned. The objective was to quantify the antibody titers of the users treated at the HISTOLAB Clinical and Histopathological Laboratory and to evaluate how long they persist in the blood after a SARS-CoV-2 infection. A descriptive, longitudinal, retrospective and quantitative design was used. The population was 96 users diagnosed with SARS-CoV-2 and with more than 2 determinations of IgG and IgM antibodies against COVID-19 evaluated by chemiluminescence assay. The average age was 52.20 years, with a predominance of men (53.13%). He (72.92%) presented IgG antibody titers > 51UI in the second test. According to age and sex, only (1.04%) of men > 65 years of age, IgG antibodies persisted with levels > 100 IU for more than 60 days. It was concluded that users older than 65 years attended in the HISTOLAB clinical and histopathological laboratories had lower adaptive immunity to SARS-CoV-2.

Downloads

Download data is not yet available.

References

Terpos E y col. Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms. 2020;: p. 8(12):1885. Disponible en:https://www.mdpi.com/2076-2607/8/12/1885/htm.

Hall V y col. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in gland: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;: p. 397(10283):1459-1469. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00675-9/fulltext.

Röltgen K y col. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;: p. 5(54):eabe0240. Disponible en: https://immunology.sciencemag.org/content/5/54/eabe0240.

Turner J y col. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;: p. 595(7867):421-425. Disponible en: https://www.nature.com/articles/s41586-021-03647-4.

Chirathaworn C y col. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020. PLoS One. 2020;: p. 15(10):e0236905. Disponible en:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236905.

Wang Y y col. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol. 2021;: p. 90:107271. Disponible en:https://www.sciencedirect.com/science/article/pii/S1567576920337383?via%3Dihub.

Yadav A y col. Seroconversion among COVID-19 patients admitted in a dedicated COVID hospital: A longitudinal prospective study of 1000 patients. Med J Armed Forces India. 2021;: p. 77:S379-S384. Disponible en:https://www.sciencedirect.com/science/article/pii/S0377123721001532?via%3Dihub.

Zurochka A y col. Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than rsons Who Are at Increased Risk Exposure: The Results of the Single-Center Prospective, Cross-Sectional Study. Vaccines (Basel). 2021;: p. 9(6):627. Disponible en: https://www.mdpi.com/2076-393X/9/6/627.

Orner E y col. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities. Diagn Microbiol Infect Dis. 2021;: p. 99(4):115300. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0732889320306775?via%3Dihub.

Long Q y col. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;: p. 26(6): 845-848. Disponible en: https://www.nature.com/articles/s41591-020-0897-1.

Luo C y col. Dynamic changes and prevalence ARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors. Int J Infect Dis. 2021;: p. 108:57-62. Disponible en:https://www.ijidonline.com/article/S1201-9712(21)00389-1/fulltext.

MSP.. Ecuador activa semáforo de protección COVID-19. Ministerio de Salud Pública. 2022;: p. Disponible en: https://www.salud.gob.ec/ecuador-activa-semaforo-de-proteccion-covid-19/.

MSP. Se registra un rebrote de COVID-19 en el país.. Ministerio de Salud Pública. 2022;: p. Disponible en: https://www.salud.gob.ec/se-registra-un-rebrote-de-covid-19-en-el-pais/#:~:text=El%2018%20de%20julio%20de,diagn%C3%B3sticos%20positivos%20para%20esta%20enfermedad.

Zhao J y col. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;: p. 71(16):2027-2034. Disponible en:https://academic.oup.com/cid/article/71/16/2027/5812996.

Klein S y col. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;: p. 130(11):6141-6150. DOI: 10.1172/JCI142004..

Al-Mughales J y col. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study. Front Immunol. 2021;: p. 12:705441. DOI: 10.3389/fimmu.2021.705441..

Alvarado M y col. Seroprevalencia y seguimiento de anticuerpos IgG contra SARS-CoV-2 en personal del Laboratorio Estatal de Salud Pública de Guanajuato LaESaP. Nova scientia. 2021;: p. 13(spe). DOI: https://doi.org/10.21640/ns.v13ie.2797.

Amjadi M y col. Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. Immunohorizons. 2021;: p. 5(6):466-476. DOI: 10.4049/inmunohorizontes.2100022..

Chen Y y col. Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China. J Med Virol. 2021;: p. 93(5):2782-2789. DOI: 10.1002/jmv.26617..

Guo J y col. Detection and predictors of anti-SARS-CoV-2 antibody levels in COVID-19 patients at 8 months after symptom onset. Future Virol. 2021;: p. 0(0):10.2217/fvl-2021-0141. DOI:10.2217/fvl-2021-0141.

Tan M y col. SARS-CoV-2 Antibodies and Associated Factors at Different Hospitalization Time Points in 192 COVID-19 Cases. J Appl Lab Med. 2021;: p. 6(5):1133-1142. DOI:10.1093/jalm/jfab003.

Kotsiou O y col. Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community. Int J Environ Res Public Health. 2021;: p. 19(1):407. DOI: 10.3390/ijerph19010407.

Lee Y y col. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020;: p. 81(2):e55-e58. DOI: 10.1016/j.jinf.2020.04.019.

Li C y col. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Nat Commun. 2021;: p. 12(1):4144. DOI: 10.1038/s41467-021-24230-5..

Orner E y col. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities. Diagn Microbiol Infect Dis. 2021;: p. 99(4):115300. DOI: 10.1016/j.diagmicrobio.2020.115300.

Zhu L y col. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. Microbiol Spectr. 2021;: p. 9(2):e0059021. DOI: 10.1128/Espectro.00590-21..

Vizcaíno-Carruyo J y col. COVID-19 anticuerpos IgM/IgG por ensayo inmunocromatográfico (prueba rápida). Med. Lab. 2020;: p. 24(3):255-7. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/302.